2025年1月22日，乐普生物宣布将创新ADC新药MRG007的大中华区外全球权益授权给ArriVent Biopharma。 根据许可协议，ArriVent支付4700万美元预付款和近期里程碑金额，11.6亿美元的开发、注册和销售里程碑付款，以及高个位数至低双位数百分比的销售分成。 MRG007为一款潜在同类最佳的针对消化道肿瘤的ADC新药，预计2025年上半年递交首个IND申请，重点开发结直肠癌、胰腺癌和其他消化道恶性肿瘤适应症。 乐普生物经过多年布局，建立了持续迭代的ADC技术平台和极具竞争力的ADC管线，首发的EGFR ADC已经递交上市申请并获得突破疗法认证和优先审评资格。 2024年AACR会议上，乐普生物汇报了新一代ADC技术平台Hi-TOPi，包括在此基础上开发的GPC3 ADC新药MRG006的临床前研究数据。Hi-TOPi的设计特点包括：Linker在血液循环中高度稳定，在肿瘤细胞中高效释放毒素；Payload为新型TOP1抑制剂，具有更高的活性，因其并非Pgp的底物，因此具有克服耐药性的潜力；在临床前多种肿瘤PDX模型和CDX模型中表现出优异的疗效与安全性。

Decoy’s proprietary IMP3ACT™ peptide conjugate drug design and manufacturing platform leverages machine learning (ML) and artificial intelligence (AI) tools Decoy is leveraging non-dilutive funding and equivalents from federal governments, corporations and The Bill & Melinda Gates Foundation totaling approximately $7 million Combined company expects to accelerate clinical development of novel peptide conjugate therapeutics for the treatment of respiratory viruses and cancer Jan. 13, 2025 -- Sa

Jan. 13, 2025 -- genXtraits Inc. (genXtraits) and Solis Agrosciences Inc. (Solis) today announced that they have entered into an agreement under which Solis will conduct certain R&D services for genXtraits to accelerate the genXtraits’ novel crop variety development programs. genXtraits is an innovative biotech start-up, which is developing new crop varieties that carry valuable traits such as environmental stress tolerance and improved nutritional composition. The company has a proprietary bi

Jan. 10, 2025 -- InflammX Therapeutics Inc., a clinical-stage biotechnology company focused on developing innovative therapies for retinal diseases with significant unmet needs, announced today that it has entered into an option agreement granting leading global eye health company Bausch + Lomb the right to acquire the company. This strategic move aligns with a shared goal of advancing groundbreaking treatments addressing unmet medical needs in ophthalmology. InflammX’s pipeline includes a cutt

2025年1月13日，复宏汉霖（2696.HK）宣布与Abbott签署许可协议，授予其在69个新兴市场国家和地区独家或半独家开发和商业化公司自主开发的四款生物类似药和一款生物创新药，协议覆盖亚洲、拉丁美洲和加勒比海地区及中东北非。该许可协议是在双方现有肿瘤领域生物类似药合作的基础上进一步深化。 根据新协议，预计到2027年，第一批分子候选物将上市，其余产品待完成临床开发和注册。Abbott将负责合作区域内合作产品的上市注册，并撬动其现有业务的广泛影响力和行业领导地位来推动合作产品的市场推广。作为一家专注于肿瘤、自身免疫疾病及眼科疾病的国际化生物制药公司，复宏汉霖将于其位于上海的GMP认证生产基地生产这些药物。 此次双方扩大合作，致力于令全球患者获得高质量、可负担的先进生物药，进一步兑现双方在新兴市场提供更多先进治疗选择的承诺。 复宏汉霖很高兴能与Abbott进一步加深合作。Abbott凭借其值得信赖的优质成熟药品、持续的技术创新能力以及完备的本地分销网络，于新兴市场达成稳健增长，已然成为新兴市场医疗领域的领军企业。此次双方再度携手，有力彰显了双方致力于推动全球健康可及性这一共同愿

Jan. 08, 2025 -- Mirror Biologics, Inc., specializing in development and manufacturing of immunotherapy products where the active ingredient is living, non-genetically altered, allogeneic (“off-the-shelf”) immune cells, announces that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany. The parties will collaborate to conduct a Phase II clinical trial to evaluate the combination of an experimental immunotherapy drug, AlloStim® from Mirror

January 8, 2025 – Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, and ESTEVE, an international specialty pharma company with a focus on highly specialized treatments that address significant unmet medical needs, today announced the signing of the Distribution and Licence Agreement renewal in Germany for AKYNZEO® (combination of netupitant-palonoset

Acquisition provides access to critical resources encompassing a biobank of more than 150,000 tumor specimens, 200,000 pathology slides and decades of longitudinal drug response data Data provides a critical pathway to progress AI using the high-speed computing power provided through collaboration with Nebul Combines Predictive Oncology’s AI-driven multi-omic drug discovery platform with Renovaro’s AI Cube multi-omic artificial intelligence to advance both cancer diagnostics and early drug disco

Canada and United Kingdom represent two of the largest markets within the ALK portfolio with plans to expand filings of neffy (epinephrine nasal spray) 2 mg in other key global regions Jan. 06, 2025 -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that ARS Pharma has filed for approval of neffy® (epinephrine nasal sp

– Approximately $10 million additional investment in private placement equity financing – – $1.5 million from CIRM grant first announced in June 2024 – – Cash runway guidance extended into 2026 – Jan. 06, 2025 -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has secured an additional investment of approximately $1